Jo Ingham
Impact in
- Neurology top 5%
- Long-Term Effects of COVID-19
- Infectious Diseases top 5%
- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- COVID-19 Clinical Research Studies 9
- SARS-CoV-2 and COVID-19 Research 3
-
- Long-Term Effects of COVID-19 7
- Journals
- The Lancet (3 papers)The Lancet Respiratory Medicine (3 papers)EClinicalMedicine (2 papers)Nature (2 papers)Nature Communications (1 paper)
- Partner nations
- United KingdomSwedenItaly
In The Last Decade
Jo Ingham
24 papers receiving 1.1k citations
Jo Ingham's Hit Papers
Peers
Comparison fields: 5 of 76
- Neurology 348
- Infectious Diseases 447
- Genetics 111
- Epidemiology 103
- Immunology 51
Countries citing papers authored by Jo Ingham
This map shows the geographic impact of Jo Ingham's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jo Ingham with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jo Ingham more than expected).
Fields of papers citing papers by Jo Ingham
This network shows the impact of papers produced by Jo Ingham. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jo Ingham. The network helps show where Jo Ingham may publish in the future.
No co-authors to show.
All Works
Showing the 20 most-cited of 24 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study Hit paper breakdown → | 2022 | 310 |
| 2 | Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis Hit paper breakdown → | 2022 | 231 |
| 3 | GWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19 Hit paper breakdown → | 2023 | 125 |
| 4 | 2022 | 87 | |
| 5 | Higher dose corticosteroids in patients admitted to hospital with COVID-19 who are hypoxic but not requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial Hit paper breakdown → | 2023 | 84 |
| 6 | 2023 | 62 | |
| 7 | 2023 | 60 | |
| 8 | 2024 | 27 | |
| 9 | 2021 | 26 | |
| 10 | 2023 | 25 | |
| 11 | 2024 | 24 | |
| 12 | 2023 | 22 | |
| 13 | 2023 | 17 | |
| 14 | 2024 | 17 | |
| 15 | 2023 | 16 | |
| 16 | 2023 | 13 | |
| 17 | 2023 | 9 | |
| 18 | 2023 | 8 | |
| 19 | 2024 | 6 | |
| 20 | 2025 | 5 |
About Jo Ingham
Jo Ingham is a scholar working on Infectious Diseases, Neurology, Genetics, Geriatrics and Gerontology and Obstetrics and Gynecology, having authored 24 papers that have together received 1.2k indexed citations. Recurring topics across this work include COVID-19 Clinical Research Studies (9 papers), Long-Term Effects of COVID-19 (7 papers), SARS-CoV-2 and COVID-19 Research (3 papers), Genetic Associations and Epidemiology (3 papers), Sepsis Diagnosis and Treatment (2 papers), Sleep and related disorders (1 paper), Pregnancy and preeclampsia studies (1 paper) and COVID-19 and healthcare impacts (1 paper). The work is most often cited by research in Neurology (348 citations), Infectious Diseases (447 citations), Genetics (111 citations), Epidemiology (103 citations) and Immunology (51 citations). Jo Ingham has collaborated with scholars based in United Kingdom, Sweden and Italy. Their work appears in journals such as The Lancet, The Lancet Respiratory Medicine, EClinicalMedicine, Nature and Nature Communications.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.